Memo Therapeutics https://validator.w3.org/feed/docs/rss2.html Further Information Q&A with Matthieu Delince, Director of Oncology Research Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline Contact us Expanded Access Policy About us Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio An interview with Dr David Wojciechowski, Medical Director of the Kidney Transplantation Program, UT Southwestern Medical Center Homepage Latest News Memo Therapeutics AG to Present Interim Phase II Results of Potravitug for the Treatment of BKV Infection in Kidney Transplant Recipients in a Late Breaking Oral Presentation at the World Transplant Congress Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026 An interview with Dr Joseph Gaut, Ladenson Professor of Pathology & Immunology, Washington University School of Medicine Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes Memo Therapeutics AG Publishes Phase I Safety, Tolerability, and Pharmacokinetics Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical and Translational Science An interview with Kevin Fowler, Patient Advocate Consultant and Principal, The Voice of the Patient BKV BioBoss podcast with Memo Therapeutics CEO Erik van den Berg TAVI Interview, Veronica Miller Adjunct Professor at Berkeley Public Health and Director of the Forum for Collaborative Research A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus First-In-Human, Randomized, Placebo-Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults The World Transplant Congress An interview with Dr Nadiesda Costa, Associate Professor of Medicine, Medstar Georgetown University Hospital Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting Q&A with William Fitzsimmons, Transplant Therapeutics Consortium Executive Committee Member Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients in an Oral Presentation at the 63rd European Renal Association Congress Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union BIO Europe Cutting Edge of Transplantation 2025 ESMO Congress Quantification of endogenous and therapeutic IgG crossing the kidney barrier from bloodstream to urine World Kidney Day Interview, Richard Knight Jefferies Healthcare Conference Festival of Biologics Privacy Policy Q&A with Karin Hehenberger, President & Founder of Lyfebulb & Chief Medical Officer of Patient Care America ASN Kidney Week Sachs Annual Biotech in Europe Forum CICON World Transplant Congress BIO International Convention BioEquity Europe Swiss Biotech Day 2025 LSX World Congress AACR Annual Meeting Development of a conceptual model of BKV impacts on health-related quality of life in kidney transplant recipients: a qualitative study